#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute on chronic liver failure Liver transplant rejection Granulomatosis with polyangiitis Cholangitis sclerosing Autoimmune myositis Glycogen storage disease type V Alveolar proteinosis Autoimmune disorder Glioblastoma multiforme Rhabdomyosarcoma Acute myeloid leukaemia Immune-mediated renal disorder Giant cell tumour of tendon sheath Uterine leiomyosarcoma Hypoxic-ischaemic encephalopathy More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Basic Information Chronic granulomatous disease Haemophilia A without inhibitors – Basic Information Andersen-Tawil syndrome Prolymphocytic leukaemia Focal segmental glomerulosclerosis – Basic Information Mantle cell lymphoma stage III – Treatment Angiosarcoma metastatic – Trials in Disease Factor IX deficiency – Life with Disease Synovial sarcoma metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dasiglucagon Suxamethonium Chloride TUB-030 Leflunomide Op-1250 Vudalimab 204-NETU Blinatumomab Azd9550 Clindamycin Phosphate Cholic Acid IHMA-2121771-1 Dcc-3116 Isotretinoin Tafasitamab Follitropin Alfa Etravirine Amitriptyline Cevostamab Levamlodipine Succinate More therapies…

    Learn about Your Condition

    Malignant melanoma stage III Lung transplant Immune-mediated enterocolitis Perinatal depression Von Willebrand's disease Procedural haemorrhage Radiation skin injury Malignant melanoma stage II Petit mal epilepsy Erythema migrans Neurofibrosarcoma Ovarian cancer stage IV Retinoblastoma Hairy cell leukaemia recurrent Malignant melanoma of eyelid More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Study of cilostazol and nimodipine combination to improve outcomes in patients with aneurysmal subarachnoid hemorrhage

    Recruiting

    3 1 1
    Investigated Diseases:
    • Subarachnoid haemorrhage
    Investigated Drugs:
    • CILOSTAZOL
    France

  • Study on Daratumumab for Reducing Symptoms in Patients with Moderate to Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    Recruiting

    2 1 1
    Investigated Drugs:
    • HYALURONIDASE
    • Daratumumab
    Norway

  • Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

    Recruiting

    3 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Remibrutinib
    Belgium France Germany Italy The Netherlands Poland +2

  • Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer’s disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Trisomy 21
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Levetiracetam
    Spain

  • Study of TAK-360 tablets to evaluate safety and effectiveness in people with Idiopathic Hypersomnia

    Recruiting

    2 1
    France Italy Spain

  • Long-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2

    Recruiting

    4 1 1
    Investigated Diseases:
    • Hypersomnia
    • Narcolepsy
    Investigated Drugs:
    • Alks 2680
    Belgium Czechia France Italy The Netherlands Spain
Previous Page
1 … 18 19 20 21 22 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!